Danny cheng
Technology Investor, Homily Charts & Technical Analysis
ImmunityBio's falling whale accumulation is accompanying its continuing downtrend. It has declined to 25.78%; if the dip deepens, $7.19 is the next momentum support, while $8.10 remains near-term resistance. A previous descending blue ribbon's pullback or consolidation lasted roughly one month. x.comÂ
ImmunityBio's whale accumulation has fallen to 41%, well below the 75% typically needed to sustain an uptrend. The stock has continued lower after a temporary top, breaking the $8.77 and $8.40 momentum levels; remaining below them risks a test of $7.70-$7.80. Reclaiming those levels is needed to rebuild momentum. x.comÂ
ImmunityBio's market cap still looks absurd despite falling sharply from its bubble-era level. Its merger of several companies at the 2021 peak has kept the stock off the buy list. x.comÂ
ImmunityBio is too early to own because its market is not one where the best technology simply wins. Anktiva could be groundbreaking, but the field involves a lot of politics, and sales and adoption are scaling fairly slowly, which is normal. The company is worth watching. x.comÂ
ImmunityBio, Kosmos Energy, Sidus Space, bioAffinity, AXT, Satellogic, Sky Quarry, Viavi, Lightwave Logic and Qnity Electronics are stocks that can continue to double, with money flowing into the group. Worth keeping a close eye on. x.com x.comÂ
ImmunityBio combines real revenue with a real catalyst, alongside real biotech risk. Its cancer immunotherapy ANKTIVA posted a record $50.7M quarter, its eighth straight quarter of growth, and an FDA decision on expanded approval is due January 6, 2027. x.comÂ
Consumer biotech has reached its iPhone moment, as a dog with cancer was vibe coded back to life in 2026. x.comÂ
The AI and biology basket now adds AbCellera and Hims & Hers and looks set to destroy the market over the next 10 years. ImmunityBio is the immune system's operating system, Nautilus is the Tesla of proteomics, Recursion is superhuman biology-chemistry AI, AbCellera is the machine that can hit any target in the body, and Hims & Hers is the dominant direct-to-consumer distribution layer. x.comÂ
ImmunityBio is worth adding to because the company claims it can cure cancer, and the chart is very clean. x.comÂ
ImmunityBio is an easy long-term hold because it already sells an FDA-approved product, ANKTIVA for certain bladder cancers, while its valuation largely ignores an unproven pipeline in lung, brain, pancreatic and other cancers. Saudi Arabia approved ANKTIVA for bladder and non-small cell lung cancer, the first lung approval, as an international rollout builds. Founder Patrick Soon-Shiong has decades of oncology experience. Value depends on clinical data, and regular capital raises are expected. … Show more
